AZD3470

AZD3470 is a small-molecule drug developed by AstraZeneca. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency. ClinicalTrials.gov describes the intervention as: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hodgkin lymphoma and peripheral T-cell lymphomas. The largest, NCT06130553, plans to enrol 334 participants with primary completion expected 2028-12-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.